Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer

详细信息    查看全文

• 作者：P. Jiménez-Fonseca ; M. P. Solis ; M. Garrido ; L. Faez…
• 关键词：Refractory metastatic colorectal cancer ; Gemcitabine ; Capecitabine ; Third ; line chemotherapy ; Progression ; free survival ; Overall survival
• 刊名：Clinical and Translational Oncology
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：17
• 期：5
• 页码：384-392
• 全文大小：1,688 KB
• 参考文献：1.Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol. 2004;22(19):3950-.View Article PubMed
  2.Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cáncer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-2.View Article PubMed
  3.Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2,2-difluoro 2-deoxycytidine on DNA synthesis. Cancer Res. 1991;5:6110-.
  4.Heineman V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Inhibition of ribonulceotide reduction in CCRF-CLM cells by 2, 2-difluoro-2-deoxycytidine. Mol Pharmacol. 1990;38:567-2.
  5.Schilsky RL. Pharmacology and clinical studies of capecitabine. Oncology. 2000;14:1297-06.PubMed
  6.Ren Q, Kao V, Grem JL. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro 2-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res. 1998;4:2811-.PubMed
  7. http://?www.?recist.?com/?recist-in-practice/-1.?html .
  8. http://?ecog.?dfci.?harvard.?edu/?general/?perf_?stat.?html .
  9. http://?evs.?nci.?nih.?gov/?ftp1/?CTCAE/?CTCAE_-.-3_-010-06-14_?QuickReference_-x7.?pdf .
  10.Wang CC, Li J. An update on chemotherapy of colorectal liver metastases. World J Gastroenterol. 2012;18(1):25-3.View Article PubMed Central PubMed
  11.Eng C. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist. 2010;15(1):73-4.View Article PubMed Central PubMed
  12.Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658-4.View Article PubMed
  13.Bitossi R, Sculli CM, Tampellini M, Alabiso I, Brizzi MP, Ferrero A, et al. Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res. 2008;28(5B):3055-0.PubMed
  14.Schulz L, Schalhorn A, Wilmanns W, Heinemann V. Synergistic interactions of gemcitabine and 5-FU in colon cancer cells. Proc Am Soc Clin Oncol 1998; 17: 251a(abstr 965).
  15.Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002;20(2):582-.View Article PubMed
  16.Madajewicz S, McCann P, Hentschel P. Gemcitabine enhanced biochemical modulation of 5-fluorouracil (5-FU) and folinic acid (FA): an effective treatment for metastatic colorectal carcinoma. Proc GI Cancers Symp 2004; 1(1): abstract 267.
  17.Fillos T, Hentschel P, Dacosta N. Phase II study of 5-fluorouracil, folinic acid, and gemcitabine in heavily pretreated metastatic colorectal cancer. Proc GI Cancers Symp 2005; 1(1): abstract 268.
  18.Qiu M, Bi J, Liu Q, Li Q, Yi C. Gemcitabine and capecitabine as third-line treatment in patients with metastatic colorectal cáncer after failure of irinotecan and oxaliplatin. J Clin Oncol 2011; 29(suppl 4): abstr 620.
  19.Pachon V, Garcia-Alfonso P, Iglesias L, Siso I, Abad G, Koshravi P, et al. Gemcitabine plus continuous infusion of 5-FU for heavily pretreated advanced colorectal cancer patients. Phase I/II study. J Clin Oncol 2005; 23(16S Part I): abstract 3735.
  20.Madajewicz S, Hentschel P, Burns P, Caruso R, Fiore J, Fried M, et al. Phase I chemotherapy study of biochemical modulation of folinic Acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J Clin Oncol. 2000;18(20):3553-.PubMed
  21.Fernandez Y, Vieitez JM, Fra J, Palacio I, Mareque B, U?a E, et al. Capecitabine plus gemcitabine in heavily pre-treated colorectal cancer. Results of an exploratory study. J Clin Oncol 2004; 22(14S): abstract 3679.
  22.Merl M, Hoimes C, Pham T, Saif MW. Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer?. A review of the literature. Expert Opin Investig Drugs. 2009;18:1257-4.View Article PubMed
  23.Choi JG, Seo JH, Oh SC, Choi CW, Kim JS. A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic cancer. Cancer Res Treat. 2012;44(2):127-2.View Article PubMed Central PubMed
  24.Bennouna J, Sastre J, Arnold D, ?sterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29-7.View Article PubMed
  
• 作者单位：P. Jiménez-Fonseca (1)
  M. P. Solis (1)
  M. Garrido (2)
  L. Faez (1)
  D. Rodriguez (1)
  A. L. Ruiz (1)
  M. L. Sanchez Lorenzo (1)
  E. Uriol (1)
  M. D. Menendez (1)
  J. M. Viéitez (1)
  
  1. Medical Oncology Department, Asturias Central University Hospital, Carretera de Rubín s/n Finca “La Cadellada- 33011, Oviedo, Asturias, Spain
  2. Hemato-Oncology Department, Pontifical Catholic University, Santiago, Chile
  
• 刊物主题：Oncology;
• 出版者：Springer Milan
• ISSN：1699-3055

文摘

Purpose A proportion of patients with metastatic colorectal cancer (mCRC) are still able to continue with active therapy after their progression to fluoropyrimidines, oxaliplatin, and irinotecan regimens. Studies suggest that gemcitabine and fluoropyrimidines are synergic antimetabolites. The purpose was to evaluate gemcitabine–capecitabine (Gem–Cape) in heavily pretreated mCRC and to thus assess possible predictive factors for progression-free survival (PFS) and overall survival (OS). Patients and methods This analysis was performed on 119 evaluable patients pretreated with fluoropyrimidines, oxaliplatin, irinotecan, and biological agents between June 2001 and July 2011. Patients received gemcitabine 1,000?mg/m2?day 1 and capecitabine 1,000?mg/m2 bid for 7?days every 2?weeks. Results The general characteristics were ECOG 0-, 89?%; male, 68?%, and median age 63?years. In total, 61?% had received two chemotherapy lines, while 39?% had received three or more. Objective response rates and stable disease rates at 3?months were 6.72 and 37.81?%, equalling a clinical benefit of 44.53?%. The median PFS and OS were 2.87?months [95?% confidence interval (CI) 2.53-.17?months] and 6.53?months (95?% CI 5.33-.77), respectively. The most frequent toxicities were grades 1-, anemia (22?%), thrombocytopenia (10?%), and hand–foot syndrome (9?%); grade ?, diarrhea (2?%), with no treatment-related discontinuations. No treatment-related deaths were reported. Statistical significance was obtained by subgroups, assessing clinical benefits and objective responses for PFS and OS. Moreover, patients under 65 tended to have a better PFS. Conclusion These data suggest that Gem–Cape is a tolerable and feasible regimen, associated with clinical benefit in non-selected, heavily pretreated, mCRC patients.